Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
BackgroundSerum autoantibodies (AAbs) against tumor-associated antigens (TAAs) could be useful biomarkers for cancer detection. This study aims to evaluate the diagnostic value of autoantibody against PDLIM1 for improving the detection of ovarian cancer (OC).MethodsImmunohistochemistry (IHC) test in...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.698312/full |
| _version_ | 1818888230149292032 |
|---|---|
| author | Cuipeng Qiu Cuipeng Qiu Yaru Duan Bofei Wang Jianxiang Shi Jianxiang Shi Peng Wang Peng Wang Hua Ye Hua Ye Liping Dai Liping Dai Jianying Zhang Jianying Zhang Xiao Wang Xiao Wang |
| author_facet | Cuipeng Qiu Cuipeng Qiu Yaru Duan Bofei Wang Jianxiang Shi Jianxiang Shi Peng Wang Peng Wang Hua Ye Hua Ye Liping Dai Liping Dai Jianying Zhang Jianying Zhang Xiao Wang Xiao Wang |
| author_sort | Cuipeng Qiu |
| collection | DOAJ |
| description | BackgroundSerum autoantibodies (AAbs) against tumor-associated antigens (TAAs) could be useful biomarkers for cancer detection. This study aims to evaluate the diagnostic value of autoantibody against PDLIM1 for improving the detection of ovarian cancer (OC).MethodsImmunohistochemistry (IHC) test in tissue array containing 280 OC tissues, 20 adjacent tissues, and 8 normal ovarian tissues was performed to analyze the expression of PDLIM1 in tissues. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the autoantibody to PDLIM1 in 545 sera samples from 182 patients with OC, 181 patients with ovarian benign diseases, and 182 healthy controls.ResultsThe results of IHC indicated that 84.3% (236/280) OC tissues were positively stained with PDLIM1, while no positive staining was found in adjacent or normal ovarian tissues. The frequency of anti-PDLIM1 autoantibody was significantly higher in OC patients than that in healthy and ovarian benign controls in both training (n=122) and validation (n=423) sets. The area under the curves (AUCs) of anti-PDLIM1 autoantibody for discriminating OC from healthy controls were 0.765 in training set and 0.740 in validation set, and the AUC of anti-PDLIM1 autoantibody for discriminating OC from ovarian benign controls was 0.757 in validation set. Overall, it was able to distinguish 35.7% of OC, 40.6% of patients with early-stage, and 39.5% of patients with late-stage. When combined with CA125, the AUC increased to 0.846, and 79.2% of OC were detected, which is statistically higher than CA125 (61.7%) or anti-PDLIM1(35.7%) alone (p<0.001). Also, anti-PDLIM1 autoantibody could identify 15% (18/120) of patients that were negative with CA125 (CA125 <35 U/ml).ConclusionsThe anti-PDLIM1 autoantibody response in OC patients was positively correlated with PDLIM1 high expression in OC tissues, suggesting that the autoantibody against PDLIM1 might have the potential to be a novel serological biomarker of OC, serving as a complementary measure of CA125, which could improve the power of OC detection. |
| first_indexed | 2024-12-19T16:49:49Z |
| format | Article |
| id | doaj.art-86fbf83a4ebc4bf4904eceec97dd92b8 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T16:49:49Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-86fbf83a4ebc4bf4904eceec97dd92b82022-12-21T20:13:34ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-08-011210.3389/fimmu.2021.698312698312Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian CancerCuipeng Qiu0Cuipeng Qiu1Yaru Duan2Bofei Wang3Jianxiang Shi4Jianxiang Shi5Peng Wang6Peng Wang7Hua Ye8Hua Ye9Liping Dai10Liping Dai11Jianying Zhang12Jianying Zhang13Xiao Wang14Xiao Wang15Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaState Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, ChinaSchool of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, ChinaState Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaState Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, ChinaState Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, ChinaDepartment of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, ChinaState Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, ChinaDepartment of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaState Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaState Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaState Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, ChinaBackgroundSerum autoantibodies (AAbs) against tumor-associated antigens (TAAs) could be useful biomarkers for cancer detection. This study aims to evaluate the diagnostic value of autoantibody against PDLIM1 for improving the detection of ovarian cancer (OC).MethodsImmunohistochemistry (IHC) test in tissue array containing 280 OC tissues, 20 adjacent tissues, and 8 normal ovarian tissues was performed to analyze the expression of PDLIM1 in tissues. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the autoantibody to PDLIM1 in 545 sera samples from 182 patients with OC, 181 patients with ovarian benign diseases, and 182 healthy controls.ResultsThe results of IHC indicated that 84.3% (236/280) OC tissues were positively stained with PDLIM1, while no positive staining was found in adjacent or normal ovarian tissues. The frequency of anti-PDLIM1 autoantibody was significantly higher in OC patients than that in healthy and ovarian benign controls in both training (n=122) and validation (n=423) sets. The area under the curves (AUCs) of anti-PDLIM1 autoantibody for discriminating OC from healthy controls were 0.765 in training set and 0.740 in validation set, and the AUC of anti-PDLIM1 autoantibody for discriminating OC from ovarian benign controls was 0.757 in validation set. Overall, it was able to distinguish 35.7% of OC, 40.6% of patients with early-stage, and 39.5% of patients with late-stage. When combined with CA125, the AUC increased to 0.846, and 79.2% of OC were detected, which is statistically higher than CA125 (61.7%) or anti-PDLIM1(35.7%) alone (p<0.001). Also, anti-PDLIM1 autoantibody could identify 15% (18/120) of patients that were negative with CA125 (CA125 <35 U/ml).ConclusionsThe anti-PDLIM1 autoantibody response in OC patients was positively correlated with PDLIM1 high expression in OC tissues, suggesting that the autoantibody against PDLIM1 might have the potential to be a novel serological biomarker of OC, serving as a complementary measure of CA125, which could improve the power of OC detection.https://www.frontiersin.org/articles/10.3389/fimmu.2021.698312/fullautoantibodytumor-associated antigensovarian cancerPDLIM1diagnostic marker |
| spellingShingle | Cuipeng Qiu Cuipeng Qiu Yaru Duan Bofei Wang Jianxiang Shi Jianxiang Shi Peng Wang Peng Wang Hua Ye Hua Ye Liping Dai Liping Dai Jianying Zhang Jianying Zhang Xiao Wang Xiao Wang Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer Frontiers in Immunology autoantibody tumor-associated antigens ovarian cancer PDLIM1 diagnostic marker |
| title | Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer |
| title_full | Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer |
| title_fullStr | Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer |
| title_full_unstemmed | Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer |
| title_short | Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer |
| title_sort | serum anti pdlim1 autoantibody as diagnostic marker in ovarian cancer |
| topic | autoantibody tumor-associated antigens ovarian cancer PDLIM1 diagnostic marker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.698312/full |
| work_keys_str_mv | AT cuipengqiu serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT cuipengqiu serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT yaruduan serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT bofeiwang serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT jianxiangshi serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT jianxiangshi serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT pengwang serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT pengwang serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT huaye serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT huaye serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT lipingdai serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT lipingdai serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT jianyingzhang serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT jianyingzhang serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT xiaowang serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer AT xiaowang serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer |